Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jul;38(7):1590–1603. doi: 10.1128/aac.38.7.1590

5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.

S M Daluge 1, D J Purifoy 1, P M Savina 1, M H St Clair 1, N R Parry 1, I K Dev 1, P Novak 1, K M Ayers 1, J E Reardon 1, G B Roberts 1, et al.
PMCID: PMC284598  PMID: 7526782

Abstract

5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83) is a selective anti-human immunodeficiency virus (HIV) agent. When tested in phytohemagglutinin-stimulated normal human peripheral blood lymphocytes against fresh clinical isolates of HIV type 1 (HIV-1) obtained from patients naive to AZT (3'-azido-3'-deoxythymidine [zidovudine]), 935U83 inhibited virus growth with an average 50% inhibitory concentration (IC50) of 1.8 microM; corresponding IC50s were 0.10 microM for FLT (3'-deoxy-3'-fluorothymidine) and 0.23, 0.49, and 0.03 microM for the approved agents AZT, ddI (2',3'-dideoxyinosine), and ddC (2',3'-dideoxycytosine), respectively. Importantly, 935U83 retained activity against HIV strains that were resistant to AZT, ddI, or ddC. Of additional interest, we were unable to generate virus which was resistant to 935U83 by passaging either HXB2 (AZT-sensitive) or RTMC (AZT-resistant) strains in the presence of high concentrations of 935U83. The anabolic profile of 935U83 was similar to that of AZT, and 935U83 triphosphate was a potent inhibitor of HIV-1 reverse transcriptase. Pharmacokinetic evaluation showed good oral bioavailability (86% in mice and 60% in monkeys) and less extensive metabolism to the glucuronide relative to AZT. 935U83 showed low toxicity. In an in vitro assay for toxicity to a human erythrocyte progenitor, erythroid burst-forming unit (BFU-E), the IC50 for 935U83 (> 400 microM) was more than 1,000-fold those of FLT (0.07 microM) and AZT (0.30 microM). Mild reversible reductions in erythrocytes and associated parameters were seen in mice dosed orally with 2,000 mg of 935U83 per kg per day for 1 and 6 months. In monkeys dosed orally with up to 700 mg/kg/day for 1 and 6 months, the only possible treatment-related finding was cataracts in 1 of 12 animals given the intermediate dose of 225 mg/kg/day. At the highest doses in mice and monkeys, maximal concentrations in plasma were more than 100-fold the anti-HIV IC50s against clinical isolates. This safety profile in animals compares very favorably with that of any of the anti-HIV drugs approved to date and has led us to begin evaluation of 935U83 in patients with HIV infection.

Full text

PDF
1590

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman S., Lerman L. S. Kinetics and intermediates in the intracellular synthesis of bacteriophage T4 deoxyribonucleic acid. J Mol Biol. 1970 Jun 14;50(2):235–261. doi: 10.1016/0022-2836(70)90190-7. [DOI] [PubMed] [Google Scholar]
  2. Ames B. N., Mccann J., Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res. 1975 Dec;31(6):347–364. doi: 10.1016/0165-1161(75)90046-1. [DOI] [PubMed] [Google Scholar]
  3. Averett D. R. Anti-HIV compound assessment by two novel high capacity assays. J Virol Methods. 1989 Mar;23(3):263–276. doi: 10.1016/0166-0934(89)90159-6. [DOI] [PubMed] [Google Scholar]
  4. Ayers K. M. Preclinical toxicology of zidovudine. An overview. Am J Med. 1988 Aug 29;85(2A):186–188. [PubMed] [Google Scholar]
  5. Bailer A. J. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm. 1988 Jun;16(3):303–309. doi: 10.1007/BF01062139. [DOI] [PubMed] [Google Scholar]
  6. Balzarini J., Van Aerschot A., Pauwels R., Baba M., Schols D., Herdewijn P., De Clercq E. 5-Halogeno-3'-fluoro-2',3'-dideoxyuridines as inhibitors of human immunodeficiency virus (HIV): potent and selective anti-HIV activity of 3'-fluoro-2',3'-dideoxy-5-chlorouridine. Mol Pharmacol. 1989 May;35(5):571–577. [PubMed] [Google Scholar]
  7. Balzarini J., van Aerschot A., Herdewijn P., de Clercq E. 5-Chloro-substituted derivatives of 2', 3'-didehydro-2',3'-dideoxyuridine, 3'-fluoro-2',3'-dideoxyuridine and 3'-azido-2',3'-dideoxyuridine as anti-HIV agents. Biochem Pharmacol. 1989 Mar 15;38(6):869–874. doi: 10.1016/0006-2952(89)90273-6. [DOI] [PubMed] [Google Scholar]
  8. Blum M. R., Liao S. H., Good S. S., de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988 Aug 29;85(2A):189–194. [PubMed] [Google Scholar]
  9. CLELAND W. W. Computer programmes for processing enzyme kinetic data. Nature. 1963 May 4;198:463–465. doi: 10.1038/198463a0. [DOI] [PubMed] [Google Scholar]
  10. Chen C. H., Cheng Y. C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine. J Biol Chem. 1989 Jul 15;264(20):11934–11937. [PubMed] [Google Scholar]
  11. Chen C. H., Vazquez-Padua M., Cheng Y. C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol. 1991 May;39(5):625–628. [PubMed] [Google Scholar]
  12. Chesebro B., Wehrly K. Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol. 1988 Oct;62(10):3779–3788. doi: 10.1128/jvi.62.10.3779-3788.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Domin B. A., Mahony W. B., Koszalka G. W., Porter D. J., Hajian G., Zimmerman T. P. Membrane permeation characteristics of 5'-modified thymidine analogs. Mol Pharmacol. 1992 May;41(5):950–956. [PubMed] [Google Scholar]
  14. Domin B. A., Mahony W. B., Zimmerman T. P. Purine nucleobase transport in human erythrocytes. Reinvestigation with a novel "inhibitor-stop" assay. J Biol Chem. 1988 Jul 5;263(19):9276–9284. [PubMed] [Google Scholar]
  15. Dornsife R. E., St Clair M. H., Huang A. T., Panella T. J., Koszalka G. W., Burns C. L., Averett D. R. Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother. 1991 Feb;35(2):322–328. doi: 10.1128/aac.35.2.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Evans H. J., O'Riordan M. L. Human peripheral blood lymphocytes for the analysis of chromosome aberrations in mutagen tests. Mutat Res. 1975 Jun;31(3):135–148. doi: 10.1016/0165-1161(75)90082-5. [DOI] [PubMed] [Google Scholar]
  17. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  18. Fischl M. A., Richman D. D., Hansen N., Collier A. C., Carey J. T., Para M. F., Hardy W. D., Dolin R., Powderly W. G., Allan J. D. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med. 1990 May 15;112(10):727–737. doi: 10.7326/0003-4819-112-10-727. [DOI] [PubMed] [Google Scholar]
  19. Fisher A. G., Collalti E., Ratner L., Gallo R. C., Wong-Staal F. A molecular clone of HTLV-III with biological activity. Nature. 1985 Jul 18;316(6025):262–265. doi: 10.1038/316262a0. [DOI] [PubMed] [Google Scholar]
  20. Furman P. A., Davis M., Liotta D. C., Paff M., Frick L. W., Nelson D. J., Dornsife R. E., Wurster J. A., Wilson L. J., Fyfe J. A. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother. 1992 Dec;36(12):2686–2692. doi: 10.1128/aac.36.12.2686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Furman P. A., Fyfe J. A., St Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Lehrman S. N., Bolognesi D. P., Broder S., Mitsuya H. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333–8337. doi: 10.1073/pnas.83.21.8333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Fyfe J. A. Differential phosphorylation of (E)-5-(2-bromovinyl)-2'-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol Pharmacol. 1982 Mar;21(2):432–437. [PubMed] [Google Scholar]
  23. Fyfe J. A., Keller P. M., Furman P. A., Miller R. L., Elion G. B. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem. 1978 Dec 25;253(24):8721–8727. [PubMed] [Google Scholar]
  24. Harmenberg J., Malm M., Abele G. Deoxythymidine pools of human skin and guinea pig organs. FEBS Lett. 1985 Sep 2;188(2):219–221. doi: 10.1016/0014-5793(85)80375-6. [DOI] [PubMed] [Google Scholar]
  25. Heerdt B. G., Halsey H. K., Lipkin M., Augenlicht L. H. Expression of mitochondrial cytochrome c oxidase in human colonic cell differentiation, transformation, and risk for colonic cancer. Cancer Res. 1990 Mar 1;50(5):1596–1600. [PubMed] [Google Scholar]
  26. Ho H. T., Hitchcock M. J. Cellular pharmacology of 2',3'-dideoxy-2',3'-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus. Antimicrob Agents Chemother. 1989 Jun;33(6):844–849. doi: 10.1128/aac.33.6.844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Howell S. B., Mansfield S. J., Taetle R. Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity. Cancer Res. 1981 Mar;41(3):945–950. [PubMed] [Google Scholar]
  28. Jackson J. B., Coombs R. W., Sannerud K., Rhame F. S., Balfour H. H., Jr Rapid and sensitive viral culture method for human immunodeficiency virus type 1. J Clin Microbiol. 1988 Jul;26(7):1416–1418. doi: 10.1128/jcm.26.7.1416-1418.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Jansen R. W., Johnson L. C., Averett D. R. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chemother. 1993 Mar;37(3):441–447. doi: 10.1128/aac.37.3.441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kahn J. O., Lagakos S. W., Richman D. D., Cross A., Pettinelli C., Liou S. H., Brown M., Volberding P. A., Crumpacker C. S., Beall G. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med. 1992 Aug 27;327(9):581–587. doi: 10.1056/NEJM199208273270901. [DOI] [PubMed] [Google Scholar]
  31. Kong X. B., Zhu Q. Y., Vidal P. M., Watanabe K. A., Polsky B., Armstrong D., Ostrander M., Lang S. A., Jr, Muchmore E., Chou T. C. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother. 1992 Apr;36(4):808–818. doi: 10.1128/aac.36.4.808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Larder B. A. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1992 Dec;36(12):2664–2669. doi: 10.1128/aac.36.12.2664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Larder B. A., Chesebro B., Richman D. D. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother. 1990 Mar;34(3):436–441. doi: 10.1128/aac.34.3.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Larder B. A., Coates K. E., Kemp S. D. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol. 1991 Oct;65(10):5232–5236. doi: 10.1128/jvi.65.10.5232-5236.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  36. Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 1989 Dec 1;246(4934):1155–1158. doi: 10.1126/science.2479983. [DOI] [PubMed] [Google Scholar]
  37. Lopez-Anaya A., Unadkat J. D., Schumann L. A., Smith A. L. Pharmacokinetics of zidovudine (azidothymidine). II. Development of metabolic and renal clearance pathways in the neonate. J Acquir Immune Defic Syndr. 1990;3(11):1052–1058. [PubMed] [Google Scholar]
  38. Mahony W. B., Domin B. A., Daluge S. M., Miller W. H., Zimmerman T. P. Enantiomeric selectivity of carbovir transport. J Biol Chem. 1992 Oct 5;267(28):19792–19797. [PubMed] [Google Scholar]
  39. Mansuri M. M., Hitchcock M. J., Buroker R. A., Bregman C. L., Ghazzouli I., Desiderio J. V., Starrett J. E., Sterzycki R. Z., Martin J. C. Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus. Antimicrob Agents Chemother. 1990 Apr;34(4):637–641. doi: 10.1128/aac.34.4.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Matthes E., Lehmann C., von Janta-Lipinski M., Scholz D. Inhibition of HIV-replication by 3'-fluoro-modified nucleosides with low cytotoxicity. Biochem Biophys Res Commun. 1989 Nov 30;165(1):488–495. doi: 10.1016/0006-291x(89)91096-6. [DOI] [PubMed] [Google Scholar]
  41. Meng T. C., Fischl M. A., Boota A. M., Spector S. A., Bennett D., Bassiakos Y., Lai S. H., Wright B., Richman D. D. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med. 1992 Jan 1;116(1):13–20. doi: 10.7326/0003-4819-116-1-13. [DOI] [PubMed] [Google Scholar]
  42. Merigan T. C., Skowron G. Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. Am J Med. 1990 May 21;88(5B):11S–15S. doi: 10.1016/0002-9343(90)90415-a. [DOI] [PubMed] [Google Scholar]
  43. Motulsky H. J., Ransnas L. A. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J. 1987 Nov;1(5):365–374. [PubMed] [Google Scholar]
  44. Nottebrock H., Then R. Thymidine concentrations in serum and urine of different animal species and man. Biochem Pharmacol. 1977 Nov 15;26(22):2175–2179. doi: 10.1016/0006-2952(77)90271-4. [DOI] [PubMed] [Google Scholar]
  45. Pezeshkpour G., Krarup C., Buchthal F., DiMauro S., Bresolin N., McBurney J. Peripheral neuropathy in mitochondrial disease. J Neurol Sci. 1987 Feb;77(2-3):285–304. doi: 10.1016/0022-510x(87)90129-8. [DOI] [PubMed] [Google Scholar]
  46. Prus K. L., Averett D. R., Zimmerman T. P. Transport and metabolism of 9-beta-D-arabinofuranosylguanine in a human T-lymphoblastoid cell line: nitrobenzylthioinosine-sensitive and -insensitive influx. Cancer Res. 1990 Mar 15;50(6):1817–1821. [PubMed] [Google Scholar]
  47. Reardon J. E., Furfine E. S., Cheng N. Human immunodeficiency virus reverse transcriptase. Effect of primer length on template-primer binding. J Biol Chem. 1991 Jul 25;266(21):14128–14134. [PubMed] [Google Scholar]
  48. Reardon J. E. Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation. Biochemistry. 1992 May 12;31(18):4473–4479. doi: 10.1021/bi00133a013. [DOI] [PubMed] [Google Scholar]
  49. Reardon J. E., Miller W. H. Human immunodeficiency virus reverse transcriptase. Substrate and inhibitor kinetics with thymidine 5'-triphosphate and 3'-azido-3'-deoxythymidine 5'-triphosphate. J Biol Chem. 1990 Nov 25;265(33):20302–20307. [PubMed] [Google Scholar]
  50. Resetar A., Minick D., Spector T. Glucuronidation of 3'-azido-3'-deoxythymidine catalyzed by human liver UDP-glucuronosyltransferase. Significance of nucleoside hydrophobicity and inhibition by xenobiotics. Biochem Pharmacol. 1991 Jul 15;42(3):559–568. doi: 10.1016/0006-2952(91)90319-z. [DOI] [PubMed] [Google Scholar]
  51. Resetar A., Spector T. Glucuronidation of 3'-azido-3'-deoxythymidine: human and rat enzyme specificity. Biochem Pharmacol. 1989 May 1;38(9):1389–1393. doi: 10.1016/0006-2952(89)90177-9. [DOI] [PubMed] [Google Scholar]
  52. Richman D. D., Fischl M. A., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Hirsch M. S. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):192–197. doi: 10.1056/NEJM198707233170402. [DOI] [PubMed] [Google Scholar]
  53. Roberts G. B., Fyfe J. A., Gaillard R. K., Short S. A. Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment. J Virol. 1991 Dec;65(12):6407–6413. doi: 10.1128/jvi.65.12.6407-6413.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Rocancourt D., Bonnerot C., Jouin H., Emerman M., Nicolas J. F. Activation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells. J Virol. 1990 Jun;64(6):2660–2668. doi: 10.1128/jvi.64.6.2660-2668.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Schinazi R. F., Lloyd R. M., Jr, Nguyen M. H., Cannon D. L., McMillan A., Ilksoy N., Chu C. K., Liotta D. C., Bazmi H. Z., Mellors J. W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993 Apr;37(4):875–881. doi: 10.1128/aac.37.4.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Shaw G. M., Hahn B. H., Arya S. K., Groopman J. E., Gallo R. C., Wong-Staal F. Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science. 1984 Dec 7;226(4679):1165–1171. doi: 10.1126/science.6095449. [DOI] [PubMed] [Google Scholar]
  57. Sherman P. A., Fyfe J. A. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem. 1989 Aug 1;180(2):222–226. doi: 10.1016/0003-2697(89)90420-x. [DOI] [PubMed] [Google Scholar]
  58. Sommadossi J. P., Carlisle R. Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob Agents Chemother. 1987 Mar;31(3):452–454. doi: 10.1128/aac.31.3.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Spector T., Cleland W. W. Meanings of Ki for conventional and alternate-substrate inhibitors. Biochem Pharmacol. 1981 Jan 1;30(1):1–7. doi: 10.1016/0006-2952(81)90277-x. [DOI] [PubMed] [Google Scholar]
  60. St Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991 Sep 27;253(5027):1557–1559. doi: 10.1126/science.1716788. [DOI] [PubMed] [Google Scholar]
  61. Starnes M. C., Cheng Y. C. Cellular metabolism of 2',3'-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J Biol Chem. 1987 Jan 25;262(3):988–991. [PubMed] [Google Scholar]
  62. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653–5656. doi: 10.1073/pnas.90.12.5653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Torres R. A., Franke-Ruta G., Barr M. R. Future therapies in the management of critically ill AIDS patients. Crit Care Clin. 1993 Jan;9(1):153–176. [PubMed] [Google Scholar]
  64. Volberding P. A., Lagakos S. W., Koch M. A., Pettinelli C., Myers M. W., Booth D. K., Balfour H. H., Jr, Reichman R. C., Bartlett J. A., Hirsch M. S. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med. 1990 Apr 5;322(14):941–949. doi: 10.1056/NEJM199004053221401. [DOI] [PubMed] [Google Scholar]
  65. WILKINSON G. N. Statistical estimations in enzyme kinetics. Biochem J. 1961 Aug;80:324–332. doi: 10.1042/bj0800324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Yahagi T., Nagao M., Seino Y., Matsushima T., Sugimura T. Mutagenicities of N-nitrosamines on Salmonella. Mutat Res. 1977 Apr;48(2):121–129. doi: 10.1016/0027-5107(77)90151-8. [DOI] [PubMed] [Google Scholar]
  67. Yarchoan R., Pluda J. M., Thomas R. V., Mitsuya H., Brouwers P., Wyvill K. M., Hartman N., Johns D. G., Broder S. Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet. 1990 Sep 1;336(8714):526–529. doi: 10.1016/0140-6736(90)92085-v. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES